Even though the CDK6 activity and NET connection has not yet been demonstrated, directly in MPNs, these data provide the rationale for the therapeutic evaluation of CDK6 inhibition in MPN disease [61,68,155,220]. Here, CDK6 is linked to myeloproliferative disorder.